A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Condition(s):Advanced Solid TumorLast Updated:March 27, 2024Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Advanced Solid TumorLast Updated:March 27, 2024Active, not recruiting
Condition(s):Solid TumorLast Updated:June 5, 2023Completed
Condition(s):Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion; Recurrent IDHwt Gliomas With FGFR1-TACC1 FusionLast Updated:May 29, 2019Completed
Condition(s):Advanced Malignant Solid Neoplasm; Cholangiocarcinoma; Metastatic Malignant Solid Neoplasm; Refractory Malignant Solid NeoplasmLast Updated:September 18, 2023Active, not recruiting
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:April 3, 2023Terminated
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Fusions; Gene RearrangementLast Updated:March 8, 2024Recruiting
Condition(s):CholangiocarcinomaLast Updated:November 18, 2023Active, not recruiting
Condition(s):Non-Small Cell Lung CancerLast Updated:January 27, 2022Recruiting
Condition(s):Intrahepatic Cholangiocarcinoma; FGFR2 Gene Mutation; FGFR2 Gene Rearrangement; FGFR2 Gene TranslocationLast Updated:August 28, 2023Recruiting
Condition(s):Advanced Cholangiocarcinoma; FGFR2 Gene MutationLast Updated:July 3, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.